Latest Articles about RMD

Twin Launch by ResMed - Analyst Blog

Zacks Equity Research — Tue, 04 Jun 2013 22:26:10 Z

Leading provider of medical equipment for treating and diagnosing sleep disordered breathing (SDB) ResMed Inc. ( RMD ) recently launched its Quattro Air full face mask to aid positive

ResMed Inc. (RMD) Ex-Dividend Date Scheduled for May 17, 2013

NASDAQ.com News — Thu, 16 May 2013 17:00:04 Z

ResMed Inc. ( RMD ) will begin trading ex-dividend on May 17, 2013. A cash dividend payment of $0.17 per share is scheduled to be paid on June 18, 2013. Shareholders who purchased RMD stock

X Factor: 5 Stocks Reaching Their Ex-Dividend Date on May 17

Christopher Witrak — Fri, 10 May 2013 17:02:00 Z

Twelve stocks will reach their ex-dividend date next Friday, which is significant for investors as the seller of the stock on that date, not the buyer, receives the most recent dividend. A

Got Growth?

John Reese — Thu, 02 May 2013 21:00:00 Z

With first-quarter U.S. GDP growth falling short of expectations and few expecting much in the way of broader economic growth for the rest of the year, investors are once again considering a

ResMed's Earnings Beat; Revs Lag - Analyst Blog

Zacks Equity Research — Mon, 29 Apr 2013 22:50:33 Z

ResMed Inc. (RMD) posted adjusted earnings per share (EPS) of 59 cents in the third quarter of fiscal 2013, edging past the Zacks Consensus Estimate by a couple of cents. The results were also

ResMed Eyes Continued Growth Despite Medicare Cuts

Investor's Business Daily — Fri, 19 Apr 2013 00:07:00 Z

It's fitting that ResMed specializes in equipment to treat sleep disorders, because the company has had to convince investors not to lose sleep over the potential impact of Medicare

ResMed Protects Patent Landscape - Analyst Blog

Zacks Equity Research — Tue, 02 Apr 2013 22:18:25 Z

Recently, ResMed ( RMD ) filed parallel lawsuits in the International Trade Commission (ITC) and U.S. federal court to protect its patent landscape from its international competitor APEX

Another Study for STJ's EnligHTN - Analyst Blog

Zacks Equity Research — Sat, 23 Feb 2013 01:00:01 Z

St. Jude Medical Inc. ( STJ ) has initiated a multi-center, randomized controlled study to analyze the effectiveness of its EnligHTN Renal Denervation System in reducing major

Safeway Ticks Higher on 4Q Results - Analyst Blog

Zacks Equity Research — Sat, 23 Feb 2013 00:40:01 Z

Shares of Safeway ( SWY ) touched a new 52-week high of $23.96 on Thursday, Feb 21, 2013, following the release of the fourth-quarter results. The 17.6% surge in company's profit boosted

Symmetry Misses but Up Y-Y - Analyst Blog

Zacks Equity Research — Fri, 22 Feb 2013 22:50:01 Z

Symmetry Medical Inc. 's ( SMA ) fourth-quarter 2012 adjusted earnings of 15 cents a share missed the Zacks Consensus Estimate of 19 cents. Adjusted earnings exclude one-time items other

Align Upgraded to Neutral - Analyst Blog

Zacks Equity Research — Thu, 21 Feb 2013 01:00:01 Z

We recently upgraded Align Technology ( ALGN ) to Neutral based on its encouraging fourth-quarter 2012 results and huge opportunities in the malocclusion market. Banking on its core product

BioScrip Reaffirmed at Neutral - Analyst Blog

Zacks Equity Research — Thu, 21 Feb 2013 00:50:01 Z

We maintain our long-term Neutral recommendation on BioScrip Inc. (BIOS). Although the company has several positive catalysts to drive growth over the long haul, looming concerns keep us on the

Qiagen in Collaboration with Lilly - Analyst Blog

Zacks Equity Research — Sat, 16 Feb 2013 00:20:01 Z

In an attempt to expand its companion diagnostics portfolio, Qiagen N.V. ( QGEN ) entered into a new co-development agreement with global pharmaceutical product manufacturers Eli Lilly

Zimmer Stays at Neutral - Analyst Blog

Zacks Equity Research — Fri, 15 Feb 2013 23:30:01 Z

We recently reiterated our Neutral recommendation on Zimmer Holdings ( ZMH ), a leading orthopedic medical devices company. While we hold a favorable view regarding the company's gradually

Thermo Fisher Remains at Neutral - Analyst Blog

Zacks Equity Research — Thu, 14 Feb 2013 03:44:01 Z

We recently reiterated our Neutral recommendation on Thermo Fisher Scientific ( TMO ), a major scientific instrument maker. While we hold a favorable view regarding the company's huge